Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
76 Results for "
bleomycin
" in MedChemExpress (MCE) Product Catalog:
Products (76)
76 Results for "bleomycin" in MCE Product Catalog:
Cat. No.: HY-N14774
CAS No.: 101342-94-3
Category:
Target:
Cat. No.: HY-170839
CAS No.: 87657-67-8
Target:
Research Areas:
TRPV1-IN-3 (compound 14) is a TRPV1 inhibitor that can be used for the research of idiopathic pulmonary fibrosis. TRPV1-IN-3 affects the expression of fibrosis markers collagen I and α-SMA by inhibiting the TGF-β/Smads and MAPK pathways, thereby exerting antifibrotic activity in vitro (IC50=0.51 μM). TRPV1-IN-3 significantly inhibits collagen deposition in lung tissue, improves the alveolar structure, and also increases the survival rate of mice with pulmonary fibrosis induced by Bleomycin (HY-108345) .
Cat. No.: HY-103388
CAS No.: 1262956-64-8
Target:
Research Areas:
NCX 466 is an orally active COX-1 and COX-2 inhibitor that exhibits anti-inflammatory and analgesic effects. Additionally, NCX 466 acts as a NO donor, exerting anti-inflammatory and antioxidant effects by improving microcirculation. NCX 466 significantly reduces the levels of transforming growth factor-β (TGF-β) and oxidative stress markers (such as thiobarbituric acid reactive substances (TBARS) and 8-hydroxy-2'-deoxyguanosine (8-OHdG)), and it decreases leukocyte recruitment during inflammation by reducing myeloperoxidase (MPO) activity, thereby preventing bleomycin (HY-108345)-induced pulmonary fibrosis in mice .
Cat. No.: HY-169177
CAS No.: 3047795-60-5
Target:
Research Areas:
JNK-1-IN-4 (Compound E1) is an inhibitor for JNK, that inhibits JNK-1, JNK-2 and JNK-3 with IC50s of 2.7, 19.0 and 9.0 nM, respectively. JNK-1-IN-4 inhibits the phosphorylation of c-Jun, and reduces the expression of TGF-β1-induced EMT marker proteins, such as fibronectin and α-SMA. JNK-1-IN-4 exhibits good pharmacokinetic characteristics with a bioavailability of 69%. JNK-1-IN-4 exhibits anti-fibrotic effect in Bleomycin (HY-17565)-induced mice idiopathic pulmonary fibrosis models .
Cat. No.: HY-170846
Target:
Research Areas:
FGFRs-IN-1 (Compound A16) is the orally active inhibitor for FGFR, that inhibits FGFR1/2/3/4 with IC50s of 2.3, 7, 11, and 163 nM, respectively. FGFRs-IN-1 also inhibits VEGFR1/2/3, Abl, and Flt3 with IC50s of 61, 176, 112, 26, and 353 nM, respectively. FGFRs-IN-1 exhibits weak inhibitory efficacy against CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and inhibits epithelial-mesenchymal transition (EMT) in TGF-β1 stimulated A549 cell. FGFRs-IN-1 exhibits anti-inflammatory activity in Bleomycin (HY-17565)-induced mouse pulmonary fibrosis model and CCl4 (HY-Y0298)-induced mouse liver fibrosis model .
Cat. No.: HY-W749297A
CAS No.: 51773-86-5
Synonyms: Phleomycin D2 sulfate
Target:
Bleomycin B2 (Phleomycin D2) sulfate is a selective antitumor and antibacterial agent that induces DNA strand breaks and inhibits DNA ligase activity. The optimal pH for the activity of Bleomycin B2 sulfate is 9.1, and its efficacy is enhanced by thiol compounds or hydrogen peroxide. Bleomycin B2 sulfate undergoes enzymatic inactivation via bleomycin-inactivating enzymes, exhibits selective retention in squamous cell carcinoma, and is inactivated most rapidly in liver and kidney homogenates. Bleomycin B2 sulfate can be applied in research related to squamous cell carcinoma and other relevant studies .
Cat. No.: HY-N0353R
CAS No.: 13657-68-6
Synonyms: (+)-Curdione (Standard)
Cat. No.: HY-106364A
CAS No.: 70384-29-1
Synonyms: bleomycin PEP sulfate; Pepleomycin sulfate
Target:
Peplomycin (Bleomycin PEP) sulfate is an analog of Bleomycin (HY-108345) and an antitumor antibiotic. Peplomycin sulfate exhibits potent antitumor activity and relatively low pulmonary toxicity. Peplomycin sulfate can induce various skin abnormalities and trigger apoptosis in SSCKN cells of oral squamous cell carcinoma. Peplomycin sulfate can also induce pulmonary fibrosis. Peplomycin sulfate is applicable for the research of tumors, pulmonary fibrosis and other related diseases .
Cat. No.: HY-179645
Research Areas:
Phosphodiesterase-IN-5 is a potent, orally active and selective phosphodiesterase 10A (PDE10A) inhibitor with an IC50 of 6.2 nM. Phosphodiesterase-IN-5 shows >1612-fold selectivity over other PDEs. Phosphodiesterase-IN-5 exhibits potent antifibrotic efficacy in a Bleomycin (BLM) (HY-108345)-induced murine model of pulmonary fibrosis (PF) by blocking myofibroblast differentiation via the cAMP/PKA/CREB signaling pathway. Phosphodiesterase-IN-5 can be used for the research of PF .
Cat. No.: HY-P700626
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: BLMH; BLM Hydrolase; bleomycin Hydrolase; BMH; BH
Species:
Mouse
Source:
P. pastoris
Cat. No.: HY-184278
Target:
Research Areas:
ATX-IN-28 is an orally active autotaxin (ATX) inhibitor with an IC50 of 13.7 nM. ATX-IN-28 downregulates the expression of pro-fibrotic α-SMA, ameliorates pathological damage of lung tissues in a bleomycin (HY-108345)-induced mouse model of pulmonary fibrosis, and reduces collagen deposition. ATX-IN-28 can be used for research related to idiopathic pulmonary fibrosis .
Cat. No.: HY-129843
CAS No.: 76692-12-1
Target:
Research Areas:
CGP-15720 hydrochloride is an orally active imidazolinylurea compound with anticancer activity, which exhibits inhibitory effects on human bronchial carcinoma in nude mice and respiratory tract tumors induced by diethylnitrosamine in Syrian hamsters. CGP-15720 hydrochloride acts via a non-cytotoxic mode of action, reduces tumor area and tumor incidence, and prolongs the survival time of tumor-bearing animals. Its combination with Bleomycin (HY-108345) or CCNU (HY-13669) produces additive antitumor effects. CGP-15720 hydrochloride can be used in cancer-related research such as bronchogenic carcinoma and laryngeal carcinoma .
Cat. No.: HY-P991950
Target:
Research Areas:
Cat. No.: HY-P992066
Target:
Research Areas:
Cat. No.: HY-180556
Research Areas:
PI3K/mTOR-IN-20 is a selective dual PI3K/mTOR inhibitor. PI3K/mTOR-IN-20 demonstrates nanomolar antiproliferative effects with IC50s of 0.380 and 0.090 μM for MRC-5 and Mlg2908 cells. PI3K/mTOR-IN-20 reduces Ashcroft scores, hydroxyproline content, collagen deposition, and downregulates fibrosis-related proteins, while restoring lung architecture in a Bleomycin-induced pulmonary fibrosis model. PI3K/mTOR-IN-20 shows a favorable safety profile with steady weight recovery and no distinct liver or kidney toxicity. PI3K/mTOR-IN-20 can be used for fetal lung fibroblasts research .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
